Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
New Frontiers in Hepatocellular Carcinoma: Diagnosis, Treatment and Management
share announcement

New Frontiers in Hepatocellular Carcinoma: Diagnosis, Treatment and Management

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: closed (1 May 2024) | Viewed by 905

Special Issue Editors

Prof. Dr. Irinel Popescu

E-Mail Website
Guest Editor
Center of Digestive Diseases and Liver Transplantation, Center of Excellence in Translational Medicine - Fundeni Clinical Institute, “Titu Maiorescu” University of Medicine and Pharmacy, Bucharest, Romania
Interests: liver transplant; hepatocellular carcinoma; surgical oncology; intrahepatic cholangiocarcinoma; pancreatic surgery; colorectal carcinoma
Dr. Dan G. Duda

E-Mail Website
Guest Editor
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA
Interests: liver cancer; metastatic tumor; combination therapies; angiogenesis inhibitors; biomarker studies; cancer immunotherapy; carcinoma hepatocellular; carcinoma pancreatic ductal; metastasis; translational research and clinical trials; tumor microenvironment
Dr. Florin Botea

E-Mail Website
Guest Editor
Center of Digestive Diseases and Liver Transplantation, Center of Excellence in Translational Medicine - Fundeni Clinical Institute, “Titu Maiorescu” University of Medicine and Pharmacy, Bucharest, Romania
Interests: hepatocellular carcinoma; cirrhosis laparoscopic surgery; liver surgery; hepatobiliary surgery; liver transplantation; liver cirrhosis; liver diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue focuses on the current role of surgery in the treatment of hepatocellular carcinoma, based on liver transplantation, liver resection and intraoperative tumor ablation. We are particularly interested in clinical evidence regarding how far we can extend the indications for surgery in terms of disease presentation and technical aspects, and, on the other hand, regarding presentations where other treatments, such as percutaneous tumor ablation or stereotactic radiotherapy, may replace surgery. We are also interested in new developments in the research concerning this disease, such as new biomarkers, which would further optimize the indications for surgery and the follow-up after surgical treatments.

Prof. Dr. Irinel Popescu
Dr. Dan G. Duda
Dr. Florin Botea
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatocellular carcinoma
  • liver transplantation
  • liver resection
  • intraoperative tumor ablation
  • open liver surgery
  • minimally invasive liver resection

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 261 KiB  
Article
Role of Flex-Dose Delivery Program in Patients Affected by HCC: Advantages in Management of Tare in Our Experience
by Andrea Paladini, Marco Spinetta, Roberta Matheoud, Andrea D’Alessio, Miriana Sassone, Riccardo Di Fiore, Carolina Coda, Serena Carriero, Pierpaolo Biondetti, Domenico Laganà, Roberto Minici, Vittorio Semeraro, Gian Mauro Sacchetti, Gianpaolo Carrafiello and Giuseppe Guzzardi
J. Clin. Med. 2024, 13(8), 2188; https://doi.org/10.3390/jcm13082188 - 10 Apr 2024
Viewed by 473
Abstract
Background: Introduced in the latest BCLC 2022, endovascular trans-arterial radioembolization (TARE) has an important role in the treatment of unresectable hepatocellular carcinoma (HCC) as a “bridge” or “downstaging” of disease. The evolution of TARE technology allows a more flexible and personalized target [...] Read more.
Background: Introduced in the latest BCLC 2022, endovascular trans-arterial radioembolization (TARE) has an important role in the treatment of unresectable hepatocellular carcinoma (HCC) as a “bridge” or “downstaging” of disease. The evolution of TARE technology allows a more flexible and personalized target treatment, based on the anatomy and vascular characteristics of each HCC. The flex-dose delivery program is part of this perspective, which allows us to adjust the dose and its radio-embolizing power in relation to the size and type of cancer and to split the therapeutic dose of Y90 in different injections (split-bolus). Methods: From January 2020 to January 2022, we enrolled 19 patients affected by unresectable HCC and candidates for TARE treatment. Thirteen patients completed the treatment following the flex-dose delivery program. Response to treatment was assessed using the mRECIST criteria with CT performed 6 and 9 months after treatment. Two patients did not complete the radiological follow-up and were not included in this retrospective study. The final cohort of this study counts eleven patients. Results: According to mRECIST criteria, six months of follow-up were reported: five cases of complete response (CR, 45.4% of cases), four cases of partial response (PR, 36.4%), and two cases of progression disease (PD, 18.2%). Nine months follow-up reported five cases of complete response (CR, 45.4%), two cases of partial response (PR, 18.2%), and four cases of progression disease (PD, 36.4%). No intra and post-operative complications were described. The average absorbed doses to the hepatic lesion and to the healthy liver tissue were 319 Gy (range 133–447 Gy) and 9.5 Gy (range 2–19 Gy), respectively. Conclusions: The flex-dose delivery program represents a therapeutic protocol capable of “saving” portions of healthy liver parenchyma by designing a “custom-made” treatment for the patient. Full article
(This article belongs to the Special Issue New Frontiers in Hepatocellular Carcinoma: Diagnosis, Treatment and Management)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop